Exercise Training in Patients With Left Ventricular Assist Device (Ex-VAD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Charité - Universitätsmedizin Berlin und Deutsches Herzzentrum Berlin
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
Leipzig, Germany, 04289
- Herzzentrum Leipzig
-
München, Germany, 80992
- Klinikum rechts der Isar der Technischen Universität München und Klinikum der Universität München
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- chronic end-stage systolic heart failure
stable on left ventricular assist device, meaning
- no major change in therapeutic regime within past 4 weeks: no new additional disease modifying drug (ACE inhibitor, ARB, sacubitril, beta-blocker), no change in disease modifying drug dosage more than 50% (excluded: diuretics), no initiation of a cardiac rehabilitation for a minimum of 4 weeks
- post implantation ≥ 3 months
- expected further period on the device for a minimum of 3 months after recruitment into the study
- ability to complete the study in compliance with the protocol.
- general ability of the patient to declare willingness to participate in the trial.
- written informed consent
Exclusion Criteria:
- acute illness that does not allow exercise, including unstable heart failure, acute myocarditis, acute pericarditis, stroke
- untreated life-threatening cardiac arrhythmias
- uncontrolled hypertension
- intracardiac thrombus
- inability to perform cardiopulmonary exercise testing at least 1 minute at 20W
- uncontrolled diabetes
- uncontrolled kidney disease
- recent embolism
- concurrent, continuous, or intermittent dobutamine therapy
- complex ventricular arrhythmia at rest or appearing with exertion
- supine resting heart rate > 100 beats per minute
- severe pulmonary instability
- hemodynamically relevant valvular disorders
- significant change in cardiovascular medication within the previous 4 weeks (see inclusion criteria)
- severe anemia (hemoglobin <8 g/dl), however patients with moderate anemia (hemoglobin <11 g/dl) may be recruited if clinically stable (investigator assessment)
- clinically relevant musculoskeletal disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: usual care
|
|
|
Experimental: exercise training intervention
|
structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in maximal exercise capacity
Time Frame: after 12 weeks of treatment
|
cardiopulmonary exercise testing (CPET; peakVO2)
|
after 12 weeks of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in ventilatory efficacy
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
cardiopulmonary exercise testing (CPET; VE/VCO2 slope)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in submaximal exercise tolerance
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
6-minute-walk distance (m), anaerobic threshold (VO2 at AT)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in muscle strength
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
handgrip (kg)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in body composition
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
% fat mass
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
patient-reported measure of quality of life for patients with heart failure
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
36-Item Short Form Survey (SF-36)
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
patient-reported measure of health status
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
Patient Health Questionnaire (PHQ-9)
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
patient-reported measure of presence and severity of depression
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in echocardiographic parameters of cardiac morphology and function at rest and during exercise
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
left ventricular ejection fraction (%)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in echocardiographic parameters of cardiac morphology and function at rest and during exercise
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
left ventricular end diastolic volume (ml)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in echocardiographic parameters of cardiac morphology and function at rest and during exercise
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
left ventricular end diastolic diameters (mm)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in echocardiographic parameters of cardiac morphology and function at rest and during exercise
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
tricuspid annular plane systolic excursion (TAPSE; mm)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in markers of neuroendocrine activation
Time Frame: after 12 weeks of treatment and 12 weeks of follow-up
|
NT-proBNP (ng/l)
|
after 12 weeks of treatment and 12 weeks of follow-up
|
|
change in daily physical activity
Time Frame: up to 12 weeks of treatment and 12 weeks of follow-up
|
physical activity diary
|
up to 12 weeks of treatment and 12 weeks of follow-up
|
|
change in daily physical activity
Time Frame: up to 12 weeks of treatment and 12 weeks of follow-up
|
accelerometry
|
up to 12 weeks of treatment and 12 weeks of follow-up
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
adherence to exercise training
Time Frame: up to 12 weeks of treatment
|
accelerometry
|
up to 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Ex-VAD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.